Merck’s Zolinza Approved For Rare Skin Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
The oncologic is first in its class for treatment of cutaneous T-cell lymphoma.
You may also be interested in...
Pharmion and MethylGene Collaborate On Sirtuin Inhibitors To Treat Cancer
MethylGene could get up to $79 million in milestones, 21 percent in U.S. royalties.
Pharmion and MethylGene Collaborate On Sirtuin Inhibitors To Treat Cancer
MethylGene could get up to $79 million in milestones, 21 percent in U.S. royalties.
Merck/Ariad Form Billion-Dollar Collaboration To Develop mTOR Inhibitor For Cancers
Merck’s commitment to using biomarkers, bioinformatics and diagnostics in cancer drug development was key to the deal, Ariad CEO tells “The Pink Sheet” DAILY.